2026-05-20T03:47:28Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/229002024-11-28T19:46:58Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16975
Repisalud
author
Sanz, Jaime
author
Montoro, Juan
author
Solano, Carlos
author
Valcarcel, David
author
Sampol Mayol, Antonia
author
Ferra, Christelle
author
Parody, Rocio
author
Lorenzo, Ignacio
author
Montesinos, Pau
author
Orti, Guillermo
author
Hernandez-Boluda, Juan-Carlos
author
Balaguer-Rosello, Aitana
author
Guerreiro, Manuel
author
Carretero, Carlos
author
Sanz, Guillermo F
author
Sanz, Miguel A
author
Pinana, Jose Luis
2024-09-13T09:13:26Z
2024-09-13T09:13:26Z
2020-02
Sanz J, Montoro J, Solano C, Valcarcel D, Sampol A, Ferra C, et al. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 Feb;26(2):358-66. Epub 2019 Oct 23.
10.1016/j.bbmt.2019.10.014
1523-6536
1083-8791
Biology of Blood and Marrow Transplantation
http://hdl.handle.net/20.500.13003/17343
31655119
L2003958064
2-s2.0-85076518187
https://hdl.handle.net/20.500.12105/22900
507717100017
In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo-HSCT. The cumulative incidence of neutrophil recovery was 87% at a median of 19 days (range, 13 to 24 days) in the UCBT arm versus 100% at a median of 17 days (range, 13 to 25 days) in the haplo-SCT arm (P=.04). Platelet recovery was 70% at a median of 40 days (range, 18 to 129 days) in the UCBT arm versus 86% at a median of 24 days (range, 12 to 127 days) in the haplo-HCT arm (P=.02). Rates of acute graft-versus-host disease (GVHD) grade II-IV or grade overall chronic GVHD, and extensive chronic GVHD in the UCBT and Haplo-SCT arms were 43% versus 36% (P=.8), 9% versus 9% (P=1), 66% versus 43% (P=.04), and 41% versus 23% (P=.2), respectively. Two-year nonrelapse mortality and relapse in the 2 arms were 52% versus 23% (P=.06) and 17% versus 23% (P=.5), respectively. Two-year disease-free survival, overall survival, and GVHD/relapse-free survival in the 2 arms were 30% versus 54% (P=.2), 35% versus 59% (P=.1), and 17% versus 40% (P=.04), respectively. Our data show that in the context of an MAC regimen, haplo-SCT with PTCy provides improved outcomes compared with ATG-containing single-unit UCBT.
eng
Umbilical cord blood transplantation
Haploidentical transplantation
Alternative donor transplantation
Hematologic malignancy
Allogeneic stem cell transplantation clinical trial
Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies
research article